Previous 10 | Next 10 |
Introduction of Orbital Atherectomy in Canada Expands Treatment Options for Patients with Complex Coronary Artery Disease Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional ...
The following slide deck was published by Cardiovascular Systems, Inc. in conjunction with this event. For further details see: Cardiovascular Systems (CSII) Presents At 6 th Annual Needham Virtual Med Tech & Diagnostics 1X1 Conference - Slideshow
The FDA has approved an expanded label for Eli Lilly's (NYSE:LLY) rapid-acting insulin, Lyumjev (insulin lispro-aabc injection) 100 units/mL indicated to improve glycemic control in adults with type 1 and type 2 diabetes, to include administration via continuous subcutaneous in...
The following slide deck was published by Cardiovascular Systems, Inc. in conjunction with this event. For further details see: Cardiovascular Systems (CSII) Presents At 41st Annual Canaccord Genuity Growth Virtual Conference - Slideshow
Cardiovascular Systems, Inc. (CSII) Q4 2021 Earnings Conference Call August 4, 2021, 4:30 PM ET Company Participants Jack Nielsen – Vice President-Investor Relations & Corporate Communications Scott Ward – Chairman, President and Chief Executive Officer Jeff Points – ...
The following slide deck was published by Cardiovascular Systems, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Cardiovascular Systems, Inc. 2021 Q2 - Results - Earnings Call Presentation
Image source: The Motley Fool. Cardiovascular Systems, inc (NASDAQ: CSII) Q4 2021 Earnings Call Aug 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Cardiovascular Systems, inc (CSII) Q4 2021 Earnings Call Transcr...
Conference Call Scheduled for Today, August 4, 2021, at 3:30 PM CT (4:30 PM ET) Revenues of $71.0 million increased 66.8% compared to fourth quarter last year and increased 12.2% sequentially compared to third quarter this year Fiscal 2021 revenues increased 9.5% to ...
Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to attend three investor...
Mario13/E+ via Getty Images FibroGen courts downgrades after FDA setback for Roxadustat FibroGen (FGEN) has lost ~35.7% in the pre-market in reaction to its failure to win the endorsement from FDA’s expert panel for Roxadustat in anemia due to chronic kidney diseas...
News, Short Squeeze, Breakout and More Instantly...
Cardiovascular Systems Inc. Company Name:
CSII Stock Symbol:
NASDAQ Market:
Cardiovascular Systems Inc. Website:
Cytek Biosciences Set to Join S&P SmallCap 600 Cytek Biosciences Set to Join S&P SmallCap 600 PR Newswire NEW YORK , April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P S...
Largest randomized coronary atherectomy trial ever conducted Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today...
NEW YORK, NY / ACCESSWIRE / April 2, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: INDUS Realty Trust, Inc. (NASDAQ:I...